Jeffrey Aronin is a self-established entrepreneur in the field of Biotechnology. Jeffrey Aronin is the Chief Executive Officer of Paragon Biosciences an investment company meant to assist people with severe and rare illnesses who lack approved treatment. This biotechnology company is aimed at utilizing advanced research systems and methods to learn new diagnoses, medication, and treatments. Paragon’s objective is to discover new therapy methods that work better than existing treatment. Jeffrey Aronin is stopping at nothing to surpass the already existing treatment methods and take biotechnology to a whole new level.
Creation of New Medication
Paragon biosciences have already made their name by making 14 advanced medicines which have been approved by FDA. All this has happened under the executive leadership of Jeffrey Aronin. Even with the high ranked position gained due to the approval by FDA, Jeffrey is not satisfied and aims at providing financial aids to committed researchers. Research teams are also being allocated funds depending on the research needs to boost their dedication to developing new medications. We can, therefore, say his research team aim at finding ways to give patients healthier and longer lives with their innovative medicines.
Treating beyond Known Treatment Methods
Being the CEO, Jeffrey Aronin has an innovative mindset which boosts approaches to be used in treating patients. The man has also had a lot of experience of over 20 years in the field of biotechnology. He, therefore, has conversant knowledge and skill to develop research approaches for treating severe and rare diseases. Jeffrey Aronin believes that treating diseases goes way beyond the known concepts and methods. The team behind Jeffrey Aronin vision is one with passionate leading researchers on the field of biotechnology. Also, each company in Paragon‘s network hires researchers who have already developed present-day methods of treating rare diseases. We can, therefore, say that under the leadership of Jeffrey Aronin, Paragon has what it takes to deliver treatments for rare diseases.